	Application No.	Applicant(s)
Notice of Allowability	10/522,697	DEL RIO ZAMBRANA ET AL.
	Examiner	Art Unit
	Jason M. Nolan, Ph.D.	1626
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>10/18/2007</u> .		
2. The allowed claim(s) is/are <u>1-6,8-18 and 20-25 (now 1-23)</u> .		
<ul> <li>3.</li></ul>		
3. ☑ Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) 🔲 including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1) 🔲 hereto or 2) 🔲 to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
	•	
Attachment(s)		
1. Notice of References Cited (PTO-892)	5. Notice of Informal P	' '
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summary Paper No./Mail Dat	
3. Information Disclosure Statements (PTO/SB/08),	Paper No./Mail Dat 7. ⊠ Examiner's Amendn	nent/Comment
Paper No./Mail Date 7/13/2007  4. Examiner's Comment Regarding Requirement for Deposit	8. 🛛 Examiner's Stateme	ent of Reasons for Allowance
of Biological Material	9.	
*		
		•

## **DETAILED ACTION**

Claims 1-25 are pending in the instant application; of which Claims 7, 8, 19, & 20 are currently amended. No new claims are presented.

# Response to Amendment

Applicant's amendments, see Amendment – After Final Rejection, filed 10/18/2007, with respect to Claims 7, 8, 19, & 20 have been fully considered and are entered. The 112-enablement rejection of Claims 7, 8, & 19 has been withdrawn per amendment. The objection to the specification is withdrawn per re-submission of Tables 1 & 2. The claim objection to Claim 20 is withdrawn per amendment.

### Information Disclosure Statement

Applicants' information disclosure statement (IDS), filed on 07/13/2007 has been considered. Please refer to Applicants' copy of the 1449 submitted herein.

#### Examiner's Amendment

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Leanne Rakers and J. Timothy Keane on November 9, 2007.

Art Unit: 1626

The application has been amended as follows:

1. Delete/Cancel Claims 7 & 19. These claims are canceled without prejudice; therefore Applicants retain the right to file divisional or continuation applications on the contents thereof.

#### Statement of Reasons for Allowance

The present invention pertains to the compounds according to Formula I and methods of using these compounds for the treatment of a depression, anxiety, and/or to provide neuroprotection. The compounds according to Formula I are free of the prior art; nothing known in the art anticipates or renders the compounds of the instant application obvious. The closest prior art related to the Formula I has been made of record. One skilled in the art would be enabled to make and use the compounds taught herein for the purpose of treating said disorders via their activity as 5-HT agonists using the teachings of the Specification (assays on pages 22-24) in conjunction with the teachings in the prior art, (see IDS for multiple references linking serotonin to the treatment of a pathological state or to provide neuroprotection).

#### Conclusion

Claims 1-6, 8-18, & 20-25 are allowed and have been renumbered Claims 1-23.

Art Unit: 1626

# Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jason M. Nolan, Ph.D. whose telephone number is (571) 272-4356 and electronic mail is Jason.Nolan@uspto.gov. The examiner can normally be reached on Mon - Fri (9:00 - 5:30PM). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane can be reached on (571) 272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Jason M. Nolan, Ph.D.

Examiner Art Unit 1626 PRIMARY EXAMINER

Joseph K. McKane

Supervisory Patent Examiner

Art Unit 1626

Date: November 9, 2007